Excess all-cause mortality during COVID-19 outbreak: potential role of untreated cardiovascular disease

2020 ◽  
Author(s):  
Andrea SAGLIETTO ◽  
Fabrizio D'ASCENZO ◽  
Elena CAVARRETTA ◽  
Giacomo FRATI ◽  
Matteo ANSELMINO ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Potential Role ◽  
All Cause Mortality

scholarly journals Role of Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: An updated meta-analysis of randomized controlled trials.

2021 ◽  
Author(s):  
Hua Ma ◽  
QIng Gu ◽  
Huining Niu ◽  
Xiaohua Li ◽  
Rong Wang
Keyword(s):  
Cardiovascular Disease ◽  
Primary Prevention ◽  
Meta Analysis ◽  
Significant Risk ◽  
Diabetic Patients ◽  
Primary Endpoints ◽  
All Cause Mortality ◽  
Patients With Diabetes ◽  
Rule Out

Background: The use of Aspirin in the primary prevention of cardiovascular disease (CVD) is still a topic of debate, especially in patients with diabetes. The present meta-analysis aims to rule out the efficacy of Aspirin in patients with diabetes and to compare the effectiveness of Aspirin with a placebo (or no treatment) for the primary prevention of CVD and all-cause mortality events in people with diabetes. Materials and Methods: An extensive and systematic search was conducted in Medline (via PubMed), Cinahl (via Ebsco), Scopus, and Web of Sciences from 1988 to December 2020. A detailed literature search was conducted using Aspirin, cardiovascular disease (CVD), diabetes, and efficacy to identify trials of patients with diabetes who received Aspirin for primary prevention of CVD. Demographic details with the primary outcome of events and bleeding outcomes were analyzed. The risk of bias (RoB) in included studies was evaluated using the QUADAS-2 tool. Results: A total of 5 studies out of 13 were included with 23,570 diabetic patients; 11,738 allocated to Aspirin and 11,832 allocated to the placebo group. In patients with diabetes, there was no difference between Aspirin and placebo with respect to the risk of all-cause death with a confidence interval (CI) varying 0.63 to 1.17. In addition, there were no differences in the bleeding outcomes with an odds ratio of 1.4411 (CI 0.47 to 4.34). Conclusion: Aspirin has no significant risk on primary endpoints of cardiovascular events and the bleeding outcomes in diabetic patients compared to placebo. More research on the use of Aspirin alone or in combination with other antiplatelet drugs is required in patients with diabetes to supplement currently available research.

scholarly journals Prognostic value of arterial stiffness measurements in cardiovascular disease, diabetes, and its complications: The potential role of sodium‐glucose co‐transporter‐2 inhibitors

2020 ◽  
Vol 22 (4) ◽  
pp. 562-571 ◽  
Author(s):  
Dimitrios Patoulias ◽  
Christodoulos Papadopoulos ◽  
Konstantinos Stavropoulos ◽  
Ioanna Zografou ◽  
Michael Doumas ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Arterial Stiffness ◽  
Prognostic Value ◽  
Potential Role

scholarly journals Potential role of Anitschkow cells in cardiovascular disease in human and veterinary medicine: A review of the literature

2019 ◽  
Vol 48 (3) ◽  
pp. 201-206 ◽  
Author(s):  
Elena Colombino ◽  
Ilaria Biasato ◽  
Elena Biasibetti ◽  
Alessandra Sereno ◽  
Laura Chiappino ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Veterinary Medicine ◽  
Potential Role ◽  
Review Of The Literature

The Potential Role of Antisense Oligodeoxynucleotide Therapy for Cardiovascular Disease

Drugs ◽  
2000 ◽  
Vol 60 (2) ◽  
pp. 239-248 ◽  
Author(s):  
M. Ian Phillips ◽  
Sara M. Galli ◽  
Jawahar L. Mehta
Keyword(s):  
Cardiovascular Disease ◽  
Potential Role ◽  
Antisense Oligodeoxynucleotide

Pre-Eclamptic Pregnancies: An Opportunity to Identify Women at Risk for Future Cardiovascular Disease

2008 ◽  
Vol 4 (2) ◽  
pp. 133-135 ◽  
Author(s):  
Iasmina M Craici ◽  
Steven J Wagner ◽  
Suzanne R Hayman ◽  
Vesna D Garovic
Keyword(s):  
Systematic Review ◽  
Cardiovascular Disease ◽  
Risk Factor ◽  
Meta Analysis ◽  
Later Life ◽  
Future Studies ◽  
Increased Risk ◽  
All Cause Mortality ◽  
History Of

Evaluation of: Bellamy L, Casas JP, Hingorani AD, Williams DJ: Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. Br. Med. J. 335(7627), 974 (2007). Evidence has emerged over the years suggesting that women who develop hypertensive pregnancy disorders, most notably pre-eclampsia, are at an increased risk for cardiovascular disease later in life. In this study, a systematic review and meta-analysis were performed, assessing the future risks of cardiovascular disease, cancer and all-cause mortality in women with a history of pre-eclampsia and eclampsia. Women with a history of pre-eclampsia or eclampsia, compared with women without such a history, had an increased risk for cardiovascular disease, including a fourfold increased risk for hypertension, a twofold increased risk for ischemic heart disease, stroke and deep venous thrombosis, and a 1.5-times higher all-cause mortality. The study suggests that affected women may be eligible for preventive therapies at an earlier age, especially if future studies establish the role of pre-eclampsia as an independent cardiovascular risk factor.

scholarly journals Increased cardiovascular disease risk in the HIV-positive population on ART: potential role of HIV-Nef and Tat

2015 ◽  
Vol 24 (5) ◽  
pp. 279-282 ◽  
Author(s):  
Ting Wang ◽  
Ru Yi ◽  
Linden Ann Green ◽  
Sarvesh Chelvanambi ◽  
Michael Seimetz ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Potential Role ◽  
Disease Risk ◽  
Cardiovascular Disease Risk ◽  
Hiv Positive ◽  
Positive Population
Sign in / Sign up

Export Citation Format

Share Document